Fig. 3

LS mean (SE) change from baseline at month 3 in (A) DAS28-4(ESR) and (B) HAQ-DI. Data presented for the FAS. Non-MTX csDMARD-IR (i.e., non-MTX csDMARD-IR but not bDMARD-IR) FAS for DAS28-4(ESR)/HAQ-DI: tofacitinib 5 mg BID, n = 176/196; tofacitinib 10 mg BID, n = 199/215; placebo, n = 46/48. MTX-IR (i.e., MTX-IR but not bDMARD-IR) FAS for DAS28-4(ESR)/HAQ-DI: tofacitinib 5 mg BID, n = 888/1019; tofacitinib 10 mg BID, n = 901/1041; placebo, n = 500/577. bDMARD-IR FAS for DAS28 4(ESR)/HAQ-DI: tofacitinib 5 mg BID, n = 213/236; tofacitinib 10 mg BID, n = 207/230; placebo, n = 156/169. bDMARD biologic disease modifying antirheumatic drug, BID twice daily, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-4(ESR) Disease Activity Score in 28 joints derived from 4 measures, erythrocyte sedimentation rate, FAS full analysis set, HAQ DI Health Assessment Questionnaire-Disability Index, IR inadequate response or intolerance, LS least squares, MTX methotrexate, SE standard error